Cancer Network spoke with Hussein Abdul-Hassan Tawbi, MD, PhD, on the results of a phase II study of oral azacitidine in combination with pembrolizumab in metastatic melanoma.
Cancer Network spoke with Hussein Abdul-Hassan Tawbi, MD, PhD, associate professor at The University of Texas MD Anderson Cancer Center, on the results of a phase II study of oral azacitidine in combination with pembrolizumab in patients with metastatic melanoma. The data (abstract 9560) were presented at ASCO 2019.